Corpus Intelligence IC Memo — ST. CLARE HOSPITAL 2026-04-26 16:37 UTC
IC Memo — ST. CLARE HOSPITAL
Investment Committee Memorandum | WI | 43 beds | Grade C | EBITDA uplift $6.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST. CLARE HOSPITAL

CCN 520057 | SAUK, WI | 43 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ST. CLARE HOSPITAL is a 43-bed suburban community hospital in SAUK, WI with $86.6M in net patient revenue and a 25.1% operating margin. The hospital serves a payer mix of 46.1% Medicare, 7.3% Medicaid, and 46.6% commercial.

Thesis: Turnaround. Our ML models identify $6.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 25.1% to 32.4% (+736bps).

Net Revenue HCRIS$86.6M
Current EBITDA COMPUTED$21.7M
Operating Margin COMPUTED25.1%
Occupancy HCRIS39.0%
Revenue / Bed COMPUTED$2.0M
Net-to-Gross HCRIS33.9%
Distress Probability ML51.3%

2. Market Context & Competitive Position

150
WI Hospitals
0.4%
State Median Margin
89
Comparable Hospitals

WI has 150 Medicare-certified hospitals with a median operating margin of 0.4%. The target's margin of 25.1% places it above the state median. Among 89 size-comparable peers (22-86 beds), the median margin is 0.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (22-86), prioritizing same-state peers. 89 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST. CLARE HOSPITAL (Target)WI43$86.6M25.1%
MERCY WALWORTH HOSPITALWI25$616.4M4.4%
ST. JOSEPHS COMM. HOSPT.WI70$436.8M66.1%
ST. AGNES HOSPITALWI77$275.9M-3.0%
AURORA MEDICAL CENTER OF OSHKOWI79$222.3M17.9%
MARSHFIELD MEDICAL CENTER-EAU WI56$214.6M-21.8%
ASPIRUS STEVENS POINT HOSPITALWI82$201.4M28.9%
MONROE CLINICWI58$195.3M-4.4%
ASPIRUS RIVERVIEW HOSPITAL & CWI44$161.3M13.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.8M+210bp18mo
Cost to Collect4.5%2.5%$1.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.1M+122bp9mo
Clean Claim Rate88.0%96.0%$55K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.8M
Cost to Collect
$1.7M
Denial Rate Reduction
$1.7M
A/R Days Reduction
$1.1M
Clean Claim Rate
$55K
Total EBITDA Uplift$6.4M
Current EBITDA$21.7M
+ RCM Uplift+$6.4M
Pro Forma EBITDA$28.1M
Current Margin25.1%
Pro Forma Margin32.4%
WC Released (1x)$3.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$33.4M$206.9M6.20x44.0%
Base (11x exit)10.0x11.0x$33.4M$238.4M7.14x48.2%
Bull Case9.0x11.0x$30.1M$270.3M8.99x55.2%
Bull (12x exit)9.0x12.0x$30.1M$303.7M10.11x58.8%
Bear Case11.0x10.0x$36.7M$164.2M4.47x34.9%
Bear (11x exit)11.0x11.0x$36.7M$192.5M5.24x39.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighElevated distress probabilityModel estimates 51.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 89 hospitals with 22-86 beds
  • Same-state prioritization (n=90)
  • Comp margins: P25=-8.4% / P50=0.8% / P75=8.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.